Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #3082 on Spectrum Pharmaceutecals Inc (SPPI)
1sdestiny
02/13/22 12:24 AM
#3084 RE: antihama #3082
cuggegrosse
02/13/22 1:46 PM
#3085 RE: antihama #3082
antihama
04/18/22 1:14 PM
#3099 RE: antihama #3082
having the confirmatory trial substantially enrolled at the time of approval I think is penance for past sins by Dr Raj.
The accelerated approval program has come under scrutiny recently, primarily following the approval of Biogen’s Aduhelm to treat Alzheimer’s disease. The top issue at play for the FDA is consistent but nevertheless contentious: how to balance a lack of options versus a lack of data. In the case of Aduhelm, the agency approved the drug against the recommendations of its advisors. In a recent interview with Fierce Biotech, FDA Commissioner Robert Califf, M.D., suggested one way to improve faith in the program would be for companies to launch phase 4—also known as “confirmatory”—trials before a drug nabs approval. It was an idea he got from the agency’s oncology chief, Robert Pazdur, M.D., who noted in a separate interview with Fierce Biotech that the agency is hoping to expand the accelerated approval program in cancer.